A bipartisan initiative known as “21st Century Cures,” spearheaded by the House Energy and Commerce Committee, is aiming to keep the U.S. at the forefront of biomedical innovation.
The U.S. bio-phrama industry’s distinction as No. 1 hasn’t gone unnoticed in the rest of the world, says “A Path to 21st Century Cures,” a white paper that describes the initiatives main objectives. “[O]ther nations are now actively working to gain a competitive edge in various elements, whether through a focus on basic research or a streamlined approval process to bring new treatments to market more quickly,” according to the report.
{iframe}http://www.ideaslaboratory.com/2014/05/21/reforming-u-s-regulation-to-achieve-better-science/{/iframe}